Utopia Pharmaceuticals

What Utopia Pharmaceuticals does

Utopia Pharmaceuticals is a privately held Egyptian pharmaceutical manufacturer headquartered in 10th of Ramadan City, Sharkia, Egypt. The company operates a single modern manufacturing facility spanning 18,000 square meters in the Industria West — El Sewedy Industrial Complex, with total capital investment of EGP 1.1 billion and a workforce of approximately 1,050 production workers. Its product portfolio comprises 80 marketed pharmaceutical products spanning cardiovascular, digestive, anti-infective, genito-urinary, musculoskeletal, diabetes, analgesic, respiratory, and dietary supplement categories, with an additional 100 products in development pipeline. Manufacturing capability includes tablets, capsules, oral suspensions, sachets, and ampoules, supported by pharmaceutical track-and-trace technology and barcode serialization on every package for anti-counterfeiting compliance.

The business model is a B2B pharmaceutical sales operation targeting physicians, hospitals, and pharmacies in Egypt through an enterprise field sales force, supplemented by active participation in medical conferences (ESBJP, CardioAlex, EARTH IBD School, Arab Diabetes Forum, EGAA), continuous medical education programs, physician facility visits, and international exhibitions such as CPHI Worldwide. Approximately 85% of output serves the domestic Egyptian market and ~15% is exported to African, Arab, and European markets, supported by GMP, AMRH-GMP, and LEED certifications. The company operates a consumer sub-brand, Dr. Oxygen, covering supplements, vitamins, and pediatric wellness products. Revenue figures, pricing, and detailed financial performance are not publicly disclosed, and the company is founder/management-controlled with Dr. El Saied Kamel serving as Chairman and CEO.

Name

Utopia Pharmaceuticals

Legal name

Utopia Pharmaceutical

Website

https://utopiapharma.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Utopia Pharmaceuticals is a privately held Egyptian pharmaceutical manufacturer operating an 18,000 sqm GMP-certified facility in 10th of Ramadan City, producing 80+ generic and branded medications across cardiovascular, digestive, anti-infective, diabetes, and supplement categories at 10 million packs per month, serving Egyptian physicians and pharmacies with ~15% exports to African, Arab, and European markets.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Pharmaceutical manufacturing
• Generic medications
• Cardiovascular therapeutics
• Dietary supplements
• Pharmaceutical distribution

Headquarters

HQ city

Nasr City

HQ country

Egypt

HQ region

Africa

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Sale of pharmaceutical products including cardiovascular, digestive, genito-urinary, musculoskeletal medications and supplements through domestic market and exports
2. Export Revenue: Approximately 15% of production exported to African, Arab and European markets

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Utopia Pharmaceuticals is a private Egyptian pharmaceutical manufacturer that produces an 80-product portfolio of generic medicines and supplements, including cardiovascular, digestive, genitourinary, musculoskeletal, antiinfective, diabetes, respiratory, and analgesic categories, plus the Dr. Oxygen line of dietary supplements. The company operates an 18,000 square meter GMP-certified factory in 10th of Ramadan City producing 10 million packs monthly with 90% local component, supplying domestic pharmacies and hospitals and exporting approximately 15% of output to African, Arab, and European markets.

Product overview

Utopia Pharmaceuticals is an Egyptian pharmaceutical company operating from 10th of Ramadan City, Sharkia, Egypt. The company operates a state-of-the-art manufacturing facility spanning 18,000 square meters with EGP 1.1 billion in investments, achieving 90% local component in production and employing over 1,050 workers. The product portfolio spans multiple therapeutic categories including: Cardiovascular System (Chartoreg, Chartoreg Co, Chartoreg Plus, Chartoreg Trio, Blokatens, Downsterolin, Rosuvaling, Torseretic), Antiinfectives (Moxavidex, Torbener, Itrafungex), Digestive System (Vonopravin, Downoprazol, Alkapride, Nanazoxid, Suplfect, Quinstibowl, DR OXYGEN Laxotopia), Genito Urinary System (Urginafect, Urginafect Plus, Urginafect Oral Suspension, Dr. Oxygen Cranberry), Diabetes (Nervocitic, Downbetes, Downbetes Trio), Musculo-skeletal System (Duloxeprin, Delendrozen, Dr. Oxygen for Bone and Joint), Analgesics (Arkadolow series, Geskaprofen), Respiratory System (Levohistam, Monohexal, Qulaperafen, UtopiaCOLD), and a comprehensive SUPPLEMENTS line under the Dr. Oxygen brand (Vit D, Calcium, Active B12 and Folate, Beauty Lite, Immunity Plus, Immunity Kids, Trinutrex). The company exports approximately 15% of production to African, Arab, and European markets.

Differentiator

Problem solved

Functional benefit

Brands

• Dr. Oxygen: Product line including supplements such as Dr. Oxygen Cranberry, Dr. Oxygen Vit D, Dr. Oxygen for Bone and Joint, Dr. Oxygen Calcium, Dr. Oxygen Active B12 and Folate, Dr. Oxygen Beauty Lite, Dr. Oxygen Immunity Plus, Dr. Oxygen Immunity Kids

Products and services

• Chartoreg Telmisartan 40mg or 80mg tablets for hypertension treatment and cardiovascular risk reduction, for hypertensive patients and prescribing physicians.
• Chartoreg Co Amlodipine and Telmisartan combination tablets in 5/40mg, 10/40mg, 5/80mg, and 10/80mg strengths for hypertension treatment, for hypertensive patients and prescribers.
• Chartoreg Plus Telmisartan and Hydrochlorothiazide combination tablets for essential hypertension treatment, for hypertensive patients and prescribers.
• Chartoreg Trio Triple combination of Amlodipine 5mg, Hydrochlorothiazide 12.5mg, and Telmisartan 80mg for high blood pressure, for patients with uncontrolled hypertension on dual therapy.
• Moxavidex Moxifloxacin 400mg film-coated tablets, a fluoroquinolone antibiotic reserved for patients with limited treatment options, for physicians treating resistant bacterial infections.
• Torbener Cefdinir 300mg capsules plus 125mg/5ml and 250mg/5ml oral suspension for treating mild to moderate bacterial infections, for prescribers and pediatric/adult patients.
• Itrafungex Itraconazole 100mg hard gelatin capsules for vulvovaginal candidosis, dermatophytoses, oropharyngeal candidosis, onychomycosis, and systemic fungal conditions.
• Vonopravin Vonoprazan 10mg and 20mg film-coated tablets for gastric ulcer, duodenal ulcer, reflux esophagitis treatment, and H. pylori eradication, for gastroenterologists and patients with acid-related disorders.
• Urginafect Solifenacin Succinate 5mg and 10mg film-coated tablets for symptomatic treatment of urge incontinence and overactive bladder syndrome, for urologists and affected adult patients.
• Urginafect Plus Mirabegron 50mg plus Solifenacin 5mg modified-release film-coated tablets for overactive bladder syndrome, for urologists treating refractory cases.
• Urginafect Oral Suspension Solifenacin 1mg/ml oral suspension for neurogenic detrusor overactivity in pediatric patients and overactive bladder in adults.
• Downoprazol Omeprazole-sodium bicarbonate capsules (20mg/1100mg and 40mg/1100mg) and oral suspension for duodenal ulcer, gastric ulcer, and GERD treatment.
• Alkapride Itopride hydrochloride 50mg film-coated tablets for functional dyspepsia and chronic gastritis symptoms.
• Nanazoxid Nitazoxanide 500mg tablets and 100mg/5ml oral suspension for diarrhea caused by Giardia lamblia or Cryptosporidium parvum.
• Suplfect Herbal medicine containing milk thistle, dandelion, and echinacea extracts for hepatoprotective use and liver/gallbladder complaints.
• Quinstibowl Elobixibat 5mg film-coated tablets for chronic constipation treatment.
• Nervocitic 30 FCT Thioctic acid 600mg, Benfotiamine 80mg, and Cyanocobalamin 0.50mg film-coated tablets for diabetic neuropathy and neurodegenerative diseases.
• Duloxeprin Duloxetine delayed-release capsules (20mg, 30mg, 60mg) for diabetic peripheral neuropathic pain, chronic musculoskeletal pain, fibromyalgia, and depression.
• Trinutrex Herbal supplement containing Ginkgo biloba 60mg, Ginseng 100mg, and Royal Jelly 600mg for mental and physical health improvement.
• Delendrozen Alendronic acid 70mg with cholecalciferol 5,600 IU film-coated tablets for postmenopausal osteoporosis treatment.
• Torseretic Torsemide diuretic available in 5mg tablets, 60mg tablets, and 20mg/2ml ampules for fluid management.
• Levohistam Levocetirizine dihydrochloride 5mg tablets for respiratory allergies.
• Blokatens Amlodipine and Valsartan combination tablets (5/80mg, 5/160mg, 10/160mg) for hypertension not adequately controlled by monotherapy.
• Downsterolin Ezetimibe and Simvastatin combination (10mg/20mg or 10mg/40mg) for hypercholesterolaemia and cardiovascular event prevention.
• Geskaprofen Dexketoprofen 25mg film-coated tablets for mild to moderate pain including musculo-skeletal pain and dysmenorrhoea.
• UtopiaCOLD Combination powder for oral solution containing Acetaminophen 650mg, Diphenhydramine HCl 25mg, and Phenylephrine HCl 10mg for cold symptom relief.
• Dr. Oxygen Cranberry Cranberry 200mg, D-Mannose 600mg, and Vitamin C 30mg supplement for urinary tract health, marketed under the Dr. Oxygen brand for health-conscious consumers and pharmacy retail.
• Dr. Oxygen Vit D Vitamin D3 supplement (400 IU per 2 drops) for increasing serum vitamin D concentration, marketed under the Dr. Oxygen brand for pediatric and adult consumers.
• Dr. Oxygen for Bone and Joint Supplement containing Collagen 10g, Glucosamine 500mg, Chondroitin 449.5mg, Vitamin C 180mg, Vitamin E 30mg, and Manganese 2mg for joint protection and pain relief, marketed under the Dr. Oxygen brand.
• Imegetic Dietary supplement product marketed under Utopia's food supplements line for health-conscious consumers.
• Downbetes Diabetes management medication in 10mg/1000mg and 25mg/1000mg strengths, for endocrinologists and diabetic patients.

Quantifiable outcome

• Compensated for shortages of imported medicines resulting from import suspension or market exits
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Nine partnerships are on record, tiered minor and core.

• Egyptian Society of Back and Joint Pain (ESBJP)minorStrategic or Co-development Partner · 5 February 2026Participation in annual congress chaired by Prof. Mohamed Reda Awad; discussed updated clinical approaches and best practices
• Embassy of the Republic of SenegalcoreStrategic or Co-development Partner · 28 January 2026High-level delegation visit to pharmaceutical manufacturing facilities led by Mr. Mamadou Boye Ba, Minister Counsellor, to explore pharmaceutical manufacturing cooperation, technology transfer, and future market collaboration to support Senegal and African healthcare systems
• Egyptian Association for Research & Training in Hepatogastroenterology (EARTH)minorStrategic or Co-development Partner · 27 January 2026Participation in EARTH IBD School at Dar El-Hekma; support for continuous medical education in gastroenterology and hepatology
• Egyptian Arthroscopy Association (EGAA)minorStrategic or Co-development Partner · 25 January 2026Participation in clinical meeting in collaboration with Orthopedic Department - Ain Shams University for continuous medical education
• Faculty of Pharmacy - Zagazig UniversityminorStrategic or Co-development Partner · 14 December 2025Academic partnership with Dr. Shaimaa El-Shazly, Dean of Faculty of Pharmacy, and Dr. Nahla Younes, Vice Dean, visiting factory and recognizing Dr. El-Saeed Kamel's appointment to Chamber of Pharmaceutical Industries
• Cardiovascular Scientific Research & Education Platform (CVREP)coreStrategic or Co-development Partner · 5 November 2025Participation in World Heart Day event; Dr. El Saied Kamel spoke on industry perspectives; Dr. Noha Abdel Shakour presented on Psycho Cardiology
• CPHI Worldwide 2025coreChannel Partner/ Reseller/ Distributor · 28 October 2025International pharmaceutical exhibition participation at Booth 3.0K92 in Frankfurt, Germany; focused on manufacturing collaborations in Egypt and pharmaceutical exports
• Egyptian Drug AuthoritycoreStrategic or Co-development Partner · 12 July 2025Collaboration in pharmacy internship program for pharmacy students; Dr. Ali El Ghamrawy, Chairman of Egyptian Drug Authority, honored Utopia for training contributions
• Faculty of Pharmacy - Ain Shams UniversityminorStrategic or Co-development Partner · 1 January 2025Participation in 12th Volatile Oil Gallery organized by Faculty of Pharmacy; Dr. Noha Abdel Shakour engaged with students and innovative projects

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Cipla: Indian global generics giant with extensive cardiovascular, respiratory and anti-infective portfolio and significant presence across Africa (including ARV and chronic disease leadership) - competes with Utopia's African export ambitions and serves overlapping therapeutic categories.
• Julphar (Gulf Pharmaceutical Industries): UAE-headquartered pharmaceutical manufacturer with broad generics portfolio across MENA and exports to Africa - comparable regional incumbent operating in the same therapeutic categories and export markets that Utopia targets.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Saudi-listed pharmaceutical manufacturer with broad generics and specialty portfolio serving MENA markets - comparable broad portfolio pharmaceutical manufacturer across the same therapeutic categories that Utopia serves, though geographically focused on Saudi rather than Africa.
• Hikma Pharmaceuticals: Jordanian-headquartered global generics and specialty pharma company with MENA-origin manufacturing, deep presence in Egypt, and broad cardiovascular/anti-infectives portfolios - overlapping product categories with Utopia and competing in the same Egyptian/MENA tenders but at much larger scale.

Direct peers

• EVA Pharma: Major Egyptian pharmaceutical manufacturer headquartered in Cairo with broad generic portfolio spanning cardiovascular, anti-infectives, and supplements across Africa and MENA - directly comparable to Utopia's therapeutic focus and Egypt-anchored manufacturing model with African export ambitions.
• Pharco Pharmaceuticals: Largest private Egyptian pharma company with extensive generic manufacturing, antibiotic production (the leading MENA maker) and exports to Africa, Europe and the Arab world - same Egypt-headquartered private generics manufacturer model as Utopia with overlapping therapeutic categories.
• Amoun Pharmaceutical: Major Egyptian pharmaceutical manufacturer with broad portfolio of veterinary and human pharmaceuticals and significant exports to MENA and Africa - directly comparable to Utopia as an Egyptian private pharma manufacturer with similar therapeutic breadth.
• EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest Egyptian pharmaceutical manufacturers with a broad generics portfolio, multiple manufacturing facilities, and active exports across MENA - directly comparable to Utopia in therapeutic categories (cardiovascular, anti-infectives, GI) and distribution channels.
• Minapharm Pharmaceuticals: Egyptian pharma manufacturer with biopharmaceutical capabilities and exports across MENA/Africa, operating multiple production lines including sterile injectables and generics - comparable to Utopia in Egyptian manufacturing footprint and export-oriented generics business.

Emerging players

• Mepaco Pharmaceutical Industries: Egyptian pharmaceutical manufacturer with manufacturing facilities and product offerings in cardiovascular, GI, and anti-infectives - similar private Egyptian pharma manufacturer profile targeting local and regional markets comparable to Utopia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/utopiapharma
• Facebookfacebook.com/utopiapharmaceutical
• LinkedInlinkedin.com/company/utopia-pharmaceuticals

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Utopia Pharmaceuticals